adaptvac

Bronze Sponsor

About AdaptVac

AdaptVac is a Phase III platform technology company pioneering Virus-Like Particle (VLP) vaccines for infectious diseases and oncology. Our proprietary Tag/Catcher cVLP display platform delivers highly immunogenic, durable, and safe vaccines, enabling broad protection across multiple pathogens.

We have demonstrated cross-species efficacy, collaborating with both human and animal health companies to develop next-generation veterinary vaccines.

Core Technology 

• 1st Gen. Protein VLP Platform – Traditional protein-based cVLP vaccines
• 2nd Gen. mRNA VLP Platform – mRNA vaccines with enhanced longevity and safety

Key Features.

• Long-lasting immunity – Proven >12 months of protection
• Excellent safety – Tested in >4,000 clinical participants
• Higher peak antibody titers – Enabling >20x dose-sparing
• Reduced reactogenicity – Lower side effects vs. conventional approaches
• Broad pathogen coverage – Demonstrated efficacy across infectious diseases and self-antigens

Key Vaccine Candidates & Pipeline

Infectious Diseases

• Malaria (Transmission-Blocking Vaccine) – cVLP-based vaccine improving protection & durability
• Nipah Virus (mRNA-VLP Vaccine) – Next-gen mRNA vaccine combining speed & longevity (Ph1: Q4 2026)
• Animal Health Vaccines – Expanding VLP solutions for veterinary infectious diseases

Oncology & Self-Antigens

• HER2+ Cancer Vaccine – A novel therapeutic cancer vaccine, entering Phase 1 trials in H1 2025
• Fibrosis & Autoimmune Indications – Expanding VLP technology to chronic diseases

Partnership & Collaboration Opportunities

At WVC 2025, we seek partnerships with:

• Biopharma & vaccine developers for co-development & licensing
• Animal health companies for veterinary vaccine innovations
• Public health organizations to accelerate global vaccine access
• Academia & research institutions for next-generation vaccine R&D

Meet Us at WVC 2025

We invite partners, investors, and researchers to connect with us at WVC 2025. 

website